Lysophosphatidic acid acyltransferase-β: a novel target for induction of tumour cell apoptosis

Bibliography

• GHOSH S, STRUM JC, SCIORRA VA, DANIEL L, BELL RM: Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-etradecanoylphorbol- 13-acetate-stimulated Madin—Darby canine kidney cells. Biol. Chem. (1996) 271:8472–8480.
   Google Scholar
• ••This article demonstrates a functional connection between the rafgene and PA, and therefore a mechanism of action whereby LPAAT might contribute to the growth and viability of tumour cells, i.e., a potential target for cancer therapy.
   Google Scholar
• RIZZO MA, SHOME K, WATKINS SC, ROMERO G: The recruitment of Raf-1 to membranes is mediated by direct interaction with phosphatidic acid and is independent of association with Ras. I Biol. Chem. (2000) 275:23911–23918.
   Web of Science ®Google Scholar
• ••This article demonstrates a functional connection between the rafgene and PA, and therefore a mechanism of action whereby LPAAT might contribute to the growth and viability of tumour cells, i.e., a potential target for cancer therapy.
   Google Scholar
• FANG Y, VILELLA-BACH M, BACHMANN R, FLANIGAN A, CHEN J: Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science (2001) 294:1942–1945.
   PubMed Web of Science ®Google Scholar
• ••This article demonstrates a functional connection between the rafgene and PA, and therefore a mechanism of action whereby LPAAT might contribute to the growth and viability of tumour cells, i.e., a potential target for cancer therapy, but in this case, another molecule involved in cell signalling, mTOR, requires the product of the LPAAT enzyme.
   Google Scholar
• CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J, MATTER A: Glivec (5TI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev Drug Discov. (2002) 1:493–502.
   PubMed Web of Science ®Google Scholar
• SCHINDLER T, BORNMANN W, PELLICENA P et al.: Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 289: 1938-1942.
   Google Scholar
• •Seminal paper describing the mechanism of action of the cancer drug, Gleevec, which was critical to understanding the degree of specificity and efficacy. This is an example of the desired capability and the direction of future cancer drug development.
   Google Scholar
• HEINRICH MC, CORLESS CL, DUENSING A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 299:708–710.
   PubMed Web of Science ®Google Scholar
• APPERLEY JF, GARDEMBAS M, MELO JV et al.: Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor 11 N Engl..). Med. (2002) 347:481–487.
   Google Scholar
• ZHU J, LALLEMAND-BREITENBACH V, DE THE H: Pathways of retinoic acid- or arsenic trioxide-induced PML/RARa catabolism, role of oncogene degradation in disease remission. Oncogene (2001) 20:7257–7265.
   PubMed Web of Science ®Google Scholar
• ZHANG TD, CHEN GQ, WANG ZG et al.: Arsenic trioxide, a therapeutic agent for APL. Oncogene (2001) 20:7146–7153.
   PubMed Web of Science ®Google Scholar
• MILLER WH Jr, SCHIPPER HM, LEE JS, SINGER J, WAXMAN S: Mechanisms of action of arsenic trioxide. Cancer Res. (2002) 62:3893–3903.
   PubMed Web of Science ®Google Scholar
• ZHU J, CHEN Z, LALLEMAND-BREITENBACH V, DE THE H: How acute promyelocytic leukaemia revived arsenic. Nat. Rev Cancer (2002) 2:705–713.
   PubMed Web of Science ®Google Scholar
• KELLY LM, YU JC, BOULTON CL et al.: CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AMU. Cancer Cell (2002) 1:421–432.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, BOULTON C, KELLY LM et al.: Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell (2002) 1:433–443.
   PubMed Web of Science ®Google Scholar
• TAVERAS AG, REMISZEWSKI SW, DOLL RI et al.: Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. (1997) 5:125–133.
   PubMed Web of Science ®Google Scholar
• WORKMAN P: New drug targets for genomic cancer therapy: successes, limitations, opportunities and future challenges. Carr. Cancer Drug Targets (2001) 1:33–47.
   PubMed Web of Science ®Google Scholar
• KERBEL R, FOLKMAN J: Clinical translation of angiogenesis inhibitors. Nat. Rev Cancer (2002) 2:727–739.
   PubMed Web of Science ®Google Scholar
• MAKI RG, AWAN RA, DIXON RH, JHANWAR S, ANTONESCU CR: Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int. J. Cancer (2002) 100:623–626.
   PubMed Web of Science ®Google Scholar
• RUBIN BP, SCHUETZE SM, EARY IF et al.: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.Oncol (2002)20:3586–3591.
   Google Scholar
• JOHNSTONE RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev Drug Discov. (2002) 1:287–299.
   PubMed Web of Science ®Google Scholar
• ADAMS J: Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr: Opin. Chem. Biol. (2002) 6:493–500.
   Google Scholar
• DEVERAUX QL, SCHENDEL SL, REED IC: Antiapoptotic proteins. The bc1-2 and inhibitor of apoptosis protein families. Cardiol Gin. (2001) 19:57–74.
   Google Scholar
• MURAKAMI MS, MORRISON DK: Raf-1 without MEK? Sci. STKE (2001) 2001:E30.
   Google Scholar
• STEBBINS CE, RUSSO AA, SCHNEIDER C et al.: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell (1997) 89:239–250.
   PubMed Web of Science ®Google Scholar
• HOOD JD, BEDNARSKI M, FRAUSTO R et al.: Tumor regression by targeted gene delivery to the neovasculature. Science (2002) 296:2404–2407.
   PubMed Web of Science ®Google Scholar
• •This paper describes the use of nanopartides targeted to growing tumour vasculature as a means of specific delivery combined with targeting of the rafgene to affect growth and viability of those vessels, i.e., example of technology used to specifically target tumour growth.
   Google Scholar
• HALUSKA P, DY G, ADJEI A: Farnesyl transferase inhibitors as anticancer agents. Eui: J. Cancer (2002) 38:1685–1700.
   Google Scholar
• MCPHAIL LC, WAITE KA, REGIER DS et al.: A novel protein kinase target for the lipid second messenger phosphatidic acid. Biochim. Biophys. Acta (1999) 1439:277–290.
   PubMed Web of Science ®Google Scholar
• •This paper describes the biological activity of PA, which is relevant to the authors' hypothesis that an increase in this phospholipid may be a selective advantage for tumour cells.
   Google Scholar
• ATHENSTAEDT K, DAUM G: Phosphatidic acid, a key intermediate in lipid metabolism. Eui: Biochem. (1999) 266:1–16.
   PubMedGoogle Scholar
• HODGKIN MN, PETTITT TR, MARTIN A et al.: Diacylglycerols and phosphatidates: which molecular species are intracellular messengers? Trends Biochem. Sci. (1998) 23:200–204.
   Google Scholar
• •This paper describes the biological activity of PA, which is relevant to the authors' hypothesis that an increase in this phospholipid may be a selective advantage for tumour cells, with emphasis on the enzymes that produce PA.
   Google Scholar
• JOSEPH T, WOODEN R, BRYANT A et al.: Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem. Biophys. Res. Commun. (2001) 289:1019–1024.
   PubMed Web of Science ®Google Scholar
• KANOH H, YAMADA K, SAKANE F: Diacylglycerol kinases: emerging downstream regulators in cell signaling systems. Biochem. (Tokyo) (2002) 131:629–633.
   PubMed Web of Science ®Google Scholar
• EBERHARDT C, GRAY PW, TJOELKER LW: Human lysophosphatidic acid acyltransferase. eDNA cloning, expression, and localization to chromosome 9q34.3. J. Biol. Chem. (1997) 272:20299–20305.
   Google Scholar
• AGUADO B, CAMPBELL RD: Characterization of a human lysophosphatidic acid acyltransferase that is encoded by a gene located in the Class III region of the human major histocompatibility complex. J. Biol. Chem. (1998) 273:4096–4105.
   PubMed Web of Science ®Google Scholar
• LEUNG DW: The structure and functions of human lysophosphatidic acid acyltransferases. Front. Biosci. (2001) 6:D944–D953.
   Google Scholar
• ••This review provides more detailedinformation on LPAAT and its potential as a target for cancer therapy. It is also one of two articles that first suggested this possibility.
   Google Scholar
• AGARWAL AK, ARIOGLU E, DE ALMEIDA S et al.: AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat. Genet. (2002) 31:21–23.
   Google Scholar
• ALTSCHUL SF, MADDEN TL, SCHAFFER AA et al: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. (1997) 25:3389–3402.
   PubMed Web of Science ®Google Scholar
• NAGIEC MM, WELLS GB, LESTER RL, DICKSON RC: A suppressor gene that enables Saccharomyces cerevhiae to grow without making sphingolipids encodes a protein that resembles an Escherichia coil fatty acyltransferase. .I. Biol. Chem. (1993) 268:22156–22163.
   Web of Science ®Google Scholar
• KNUTZON DS, LARDIZABAL KD, NELSEN JS et al.: Cloning of a coconut endosperm cDNA encoding a 1-acyl-sn-glycerol-3-phosphate acyltransferase that accepts medium-chain-length substrates. Plant Physia (1995) 109:999–1006.
   PubMed Web of Science ®Google Scholar
• WEST J, TOMPKINS C, BALANTAC N et al.: Cloning and expression of two human lysophosphatidic acid acyltransferase cDNAs that stimulate cytokine induced signaling responses in cells. DNA Cell Biol. (1997) 16:691–701.
   PubMed Web of Science ®Google Scholar
• CSERZO M, WALLIN E, SIMON I, VON HEIJNE G, ELOFSSON A: Prediction of transmembrane a-helices in prokaryotic membrane proteins: the dense alignment surface method. Protein Eng. (1997) 10:673–676.
   PubMedGoogle Scholar
• DIRKS WG, MACLEOD RA, DREXLER HG: ECV304 (endothelial) is really T24 (bladder carcinoma): cell line cross-contamination at source. In Vitro Cell. Dev. Biol. Amin. (1999) 35:558–559.
   Web of Science ®Google Scholar
• SCHMIDT A, WOLDE M, THIELE C et al.: Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature (1999) 401:133–141.
   PubMed Web of Science ®Google Scholar
• WEIGERT R, SILLETTA MG, SPANO S et al.: CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid. Nature (1999) 402:429–433.
   PubMed Web of Science ®Google Scholar
• BARR FA, SHORTER J: Membrane traffic: do cones mark sites of fission? Curt: Biol. (2000) 10:R141–R144.
   Google Scholar
• LEWIN TM, WANG P, COLEMAN RA: Analysis of amino acid motifs diagnostic for the sn-glycerol-3-phosphate acyltransferase reaction. Biochemistry (Mose) (1999) 38:5764–5771.
   PubMed Web of Science ®Google Scholar
• HEATH RJ, ROCK CO: A conserved histidine is essential for glycerolipid acyltransferase catalysis. Bacteria (1998) 180:1425–1430.
   PubMed Web of Science ®Google Scholar
• TURNBULL AP, RAFFERTY JB, SEDELNIKOVA SE et al.: Analysis of the structure, substrate specificity, and mechanism of squash glycerol-3-phosphate (1)-acyltransferase. Structure (Camb) (2001) 9:347–353.
   PubMed Web of Science ®Google Scholar
• KENT C: Eukaryotic phospholipid biosynthesis. Anna. Rev Biochem. (1995) 64:315–343.
   PubMed Web of Science ®Google Scholar
• KANFERJ, KENNEDY EP: Metabolism and function of bacterial lipids: I. Metabolism of phospholipids in Escherichia coil B., J. Biol. Chem. (1963) 238:2919–2922.
   PubMed Web of Science ®Google Scholar
• KANFERJ, KENNEDY EP: Metabolism and function of bacterial lipids: II. Biosynthesis of phospholipids in Escherichia coli Biol. Chem. (2003) 239:1720–1726.
   Google Scholar
• WAGGONER DW, GOMEZ-MUNOZ A, DEWALD J, BRINDLEY DN: Phosphatidate phosphohydrolase catalyzes the hydrolysis of ceramide 1-phosphate, lysophosphatidate, and sphingosine 1-phosphate. j. Biol. Chem. (1996) 271:16506–16509.
   PubMed Web of Science ®Google Scholar
• HSU SM, RAINE L, FANGER H: Use of avidin-biotin-perwddase complex (ABC) in immunoperwddase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. I. Histochem. Cytochem. (1981) 29:577–580.
   PubMed Web of Science ®Google Scholar
• BATTIFORA H, ALSABEH R, JENKINS KA, GOWN AM: Epitope retrieval (unmasking) in immunohistochemistry. Adv. Pathol Lab. Med. (1995) 8:101–118.
   Google Scholar
• HALBERT CL, DEMERS GW, GALLOWAY DA: The E7 gene of human papillomavirus Type 16 is sufficient for immortalization of human epithelial cells. Vita (1991) 65:473–478.
   Google Scholar
• BONHAM L, HOLLENBACK D, LEUNG D, WHITE T, MORRISON D, FINNEY RE: Validation of lysophosphatidic acid acyltransferase-3 (LPAAT-I3) as a novel target for anti-cancer drug discovery and development. Proc Am. Assoc. Cancer Res. (New Orleans) (2001) 3608.
   Google Scholar
• MILLER AD, ROSMAN GJ: Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 7:980–982, 984–986, 989–990.
   Google Scholar
• SHEN Y, XU L, FOSTER DA: Role for phospholipase D in receptor-mediated endocytosis. MM. Cell. Biol. (2001) 21:595–602.
   Web of Science ®Google Scholar
• JONES D, MORGAN C, COCKCROFT S: Phospholipase D and membrane traffic. Potential roles in regulated exocytosis, membrane delivery and vesicle budding. Biochim. Biophys. Ada (1999) 1439:229–244.
   Google Scholar
• SERGEANT S, WAITE KA, HERAVI J,MCPHAIL LC: Phosphatidic acid regulates tyrosine phosphorylating activity in human neutrophils: enhancement of Fgr activity. Biol. Chem. (2001) 276:4737–4746.
   Web of Science ®Google Scholar
• PAWELCZYK T, MATECKI A: Phospholipase C-83 binds with high specificity to phosphatidylinositol 4,5-bisphosphate and phosphatidic acid in bilayer membranes. Eut: Biochem. (1999) 262:291–298.
   PubMedGoogle Scholar
• BECHOUA S, DANIEL LW: Phospholipase D is required in the signaling pathway leading to p38 MAPK activation in neutrophil-like HL-60 cells, stimulated by N-formyl-methionyl-leucyl-phenylalanine. Biol. Chem. (2001) 276:31752–31759.
   Web of Science ®Google Scholar
• LEE SD, LEE BD, HAN JM et al: Phospholipase D2 activity suppresses hydrogen peroxide-induced apoptosis in PC12 cells. Neurochem. (2000) 75:1053–1059.
   PubMed Web of Science ®Google Scholar
• BANNO Y, TAKUWA Y, AKAO Y et al:Involvement of phospholipase D in sphingosine 1-phosphate-induced activation of phosphatidylinositol 3-kinase and Akt in Chinese hamster ovary cells overexpressing EDG3.J.Biol. Chem. (2001) 276:35622–35628.
   PubMed Web of Science ®Google Scholar
• SANJUAN MA, JONES DR, IZQUIERDO M, MERIDA I: Role of diacylglycerol kinase a in the attenuation of receptor signaling. Cell Biol. (2001) 153:207–220.
   PubMed Web of Science ®Google Scholar
• TOPHAM MK, PRESCOTT SM: Diacylglycerol kinase regulates Ras activation by a novel mechanism. Cell Biol. (2001) 152:1135–1143.
   PubMed Web of Science ®Google Scholar
• JONES DR, SANJUAN MA, STONE JC, MERIDA I: Expression of a catalytically inactive form of diacylglycerol kinase a induces sustained signaling through RasGRP. FASEB J. (2002) 16:595–597.
   PubMed Web of Science ®Google Scholar
• ELBASHIR SM, HARBORTH J, LENDECKEL W et al.: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411:494–498.
   PubMed Web of Science ®Google Scholar
• WARTMANN M, DAVIS RJ: The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex. 'Bid. Chem. (1994) 269:6695–6701.
   PubMed Web of Science ®Google Scholar
• CHAN TA, HERMEKING H, LENGAUER C, KINZLER KW, VOGELSTEIN B: 14-3-3a is required to prevent mitotic catastrophe after DNA damage. Nature (1999) 401:616–620.
   PubMed Web of Science ®Google Scholar
• MOLZ L, BOOHER R, YOUNG P, BEACH D: cdc2 and the regulation of mitosis: six interacting mcs genes. Genetics (1989) 122:773–782.
   PubMed Web of Science ®Google Scholar
• FINNEY RE, BISHOP JM: Predisposition to neoplastic transformation caused by gene replacement of H-rasl. Science (1993) 260:1524–1527.
   PubMed Web of Science ®Google Scholar
• BONHAM L, HOLLENBACK D, MORRISON D, WHITE T: Lysophosphatidic acid acyltransferase-P: a novel target for anti cancer drug development. Keystone Symposium, Taos, NM, USA (2002):322.
   Google Scholar
• JAIN M, ARVANITIS C, CHU K et al.: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (2002) 297:102–104.
   PubMed Web of Science ®Google Scholar
• ••This paper describes a phenomenon oftumour cell death in response to loss of function of one oncogene. This appears to occur because that tumour cell has evolved to become 'dependent' on that gene product, more so than normal cells. This may represent a means by which a drug directed against a single gene (or gene product) could kill tumour cells even though they have acquired multiple mutations and without causing death of normal cells.
   Google Scholar
• WEINSTEIN IB: Disorders in cell circuitryduring multistage carcinogenesis: the role of homeostasis. Carcinogenesis (2000) 21:857–864.
   PubMed Web of Science ®Google Scholar
• GORRE ME, MOHAMMED M, ELLWOOD K et al.: Clinical resistance to STI-571 cancer therapy caused by BCR—ABL gene mutation or amplification. Science (2001) 293:876–880.
   PubMed Web of Science ®Google Scholar
• LA ROSEE P, JOHNSON K, O'DWYER ME, DRUKER BJ: In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Exp. Hematol. (2002) 30:729–737.
   PubMed Web of Science ®Google Scholar
• •This is another of the seminal papers describing the efficacy of a 'model' tumour-specific drug, Gleevec, (also noted in [5]).
   Google Scholar